Sareum Holdings plc

SAR

GB00BMC3RJ87

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 05:36:01 18/07/2024 pm IST			5-day change	1st Jan Change
35.45 ^GBX	-2.88%		+1.29%	-40.42%

10/07	Sareum Co-Founder & CEO Tim Mitchell steps back after twenty years	AN
10/07	Sareum CEO Switches to Part-time COO Position	MT

Sareum Holdings plc Provides Revenue Guidance for the Fiscal 2023

January 26, 2023 at 11:30 am IST

Sareum Holdings plc provided revenue guidance for the fiscal 2023. For the fiscal 2023, Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range.

Latest news about Sareum Holdings plc

Sareum Co-Founder & CEO Tim Mitchell steps back after twenty years	10/07	AN
Sareum CEO Switches to Part-time COO Position	10/07	MT
Sareum Holdings plc Announces Board and Executive Changes	10/07	CI
Sareum Holdings plc Announces Transition of Chief Executive Officer	10/07	CI
Rainbow Rare and Ecora strike Phalaborwa deal	01/07	AN
Sareum Holdings plc Announces Positive Data from SDC-1801 Phase 1 Clinical Trial	01/07	CI
Sareum Issues Shares to Settle Facility with RiverFort	23/04	MT
Sareum falls as issues shares to RiverFort Global	19/04	AN
Northcoders launches bootcamp; Schroder invests	04/04	AN
Sareum ups retail offer; SThree nabs former ITV exec	02/04	AN
Sareum to Increase Retail Offer After Oversubscription	02/04	MT
EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost	28/03	AN
Sareum Holdings plc Reports Earnings Results for the Half Year Ended December 31, 2023	28/03	CI
Sareum Holdings touts new patent allowance for autoimmune therapy	15/03	AN
Sareum Bags European Patent for Kinase Inhibitor for Autoimmune Disease	15/03	MT
Sareum shares slump on widened loss and funding talks	12/03	AN
Sareum Wraps Up Single Ascending Dose, Food Effect Study in Early-stage Trial of Autoimmune Disease Drug	15/02	MT
Sareum hails safety profile for SDC-1801 after phase 1 trial	15/02	AN
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	15/02	AN
Sareum Holdings plc Announces Completion of the Single Ascending Dose Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801	15/02	CI
Sareum's Partner Signs Deal with US Biopharma Company for Cancer Growth Blockers	02/01	MT
London stocks make largely soft start to 2024	02/01	AN
AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal	02/01	AN
Sareum soars as partner agrees SRA737 licence with US biopharma firm	02/01	AN
EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer	15/12	AN

Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.

Sector

Biotechnology & Medical Research

Calendar

15/10/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREUM HOLDINGS PLC	-40.42%	51.24M
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.68%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.06%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B
INSMED INCORPORATED	+143.76%	12.18B

Bio Therapeutic Drugs